Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice

References

1. 1.↵
   1. Rajan KB,
   2. Weuve J,
   3. Barnes LL, et al

   . Population estimate of people with clinical Alzheimer’s disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement 2021;17:1966–75 doi:10.1002/alz.12362 pmid:34043283

   CrossRefPubMed
2. 2.↵
   ADUHELM®. (aducanumab-avwa) is FDA Approved for Healthcare Professionals. https://biogencdn.com/us/aduhelm-pi.pdf. Accessed June 7, 2021
3. 3.↵
   1. Honce JM,
   2. Nagae L,
   3. Nyberg E

   . Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities. Mult Scler Int 2015;2015:e80925 doi:10.1155/2015/809252 pmid:26483978

   CrossRefPubMed
4. 4.↵
   1. Wattjes MP,
   2. Vennegoor A,
   3. Steenwijk MD, et al

   . MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 2015;86:793–98 doi:10.1136/jnnp-2014-308630 pmid:25205744

   Abstract/FREE Full Text
5. 5.↵
   1. Jack CR,
   2. Bennett DA,
   3. Blennow K, et al

   . NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14:535–62 doi:10.1016/j.jalz.2018.02.018 pmid:29653606

   CrossRefPubMed
6. 6.↵
   1. Chen G,
   2. Xu T,
   3. Yan Y, et al

   . Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 2017;38:1205–35 doi:10.1038/aps.2017.28 pmid:28713158

   CrossRefPubMed
7. 7.↵
   1. Greenberg SM,
   2. Bacskai BJ,
   3. Hernandez-Guillamon M, et al

   . Cerebral amyloid angiopathy and Alzheimer disease: one peptide, two pathways. Nat Rev Neurol 2020;16:30–42 doi:10.1038/s41582-019-0281-2 pmid:31827267

   CrossRefPubMed
8. 8.↵
   1. Tarasoff-Conway JM,
   2. Carare RO,
   3. Osorio RS, et al

   . Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 2015;11:457–70 doi:10.1038/nrneurol.2015.119 pmid:26195256

   CrossRefPubMed
9. 9.↵
   1. Miller DL,
   2. Papayannopoulos IA,
   3. Styles J, et al

   . Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease. Arch Biochem Biophys 1993;301:41–52 doi:10.1006/abbi.1993.1112 pmid:8442665

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Corriveau RA,
    2. Bosetti F,
    3. Emr M, et al

    . The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): a framework for advancing research priorities in the cerebrovascular biology of cognitive decline. Cell Mol Neurobiol 2016;36:281–88 doi:10.1007/s10571-016-0334-7 pmid:27095366

    CrossRefPubMed
11. 11.↵
    1. Karran E,
    2. Mercken M,
    3. Strooper BD

    . The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698–712 doi:10.1038/nrd3505 pmid:21852788

    CrossRefPubMed
12. 12.↵
    1. Jack CR,
    2. Knopman DS,
    3. Jagust WJ, et al

    . Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9:119–28 doi:10.1016/S1474-4422(09)70299-6 pmid:20083042

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Jack CR,
    2. Knopman DS,
    3. Jagust WJ, et al

    . Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207–16 doi:10.1016/S1474-4422(12)70291-0 pmid:23332364

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Tanzi RE

    . The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006296 doi:10.1101/cshperspect.a006296

    Abstract/FREE Full Text
15. 15.↵
    1. Brier MR,
    2. Gordon B,
    3. Friedrichsen K, et al

    . Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease. Sci Transl Med 2016;8:338ra66 doi:10.1126/scitranslmed.aaf2362 pmid:27169802

    Abstract/FREE Full Text
16. 16.↵
    1. Johnson KA,
    2. Schultz A,
    3. Betensky RA, et al

    . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016;79:110–19 doi:10.1002/ana.24546 pmid:26505746

    CrossRefPubMed
17. 17.↵
    1. Jack CR,
    2. Therneau TM,
    3. Weigand SD, et al

    . Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the National Institute on Aging-Alzheimer’s Association Research Framework. JAMA Neurol 2019;76:1174 doi:10.1001/jamaneurol.2019.1971 pmid:31305929

    CrossRefPubMed
18. 18.↵
    1. Mintun MA,
    2. Lo AC,
    3. Duggan Evans C, et al

    . Donanemab in early Alzheimer’s disease. N Engl J Med 2021;384:1691–704 doi:10.1056/NEJMoa2100708 pmid:33720637

    CrossRefPubMed
19. 19.↵
    1. Swanson CJ,
    2. Zhang Y,
    3. Dhadda S, et al

    . A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 2021;13:80 doi:10.1186/s13195-021-00813-8 pmid:33865446

    CrossRefPubMed
20. 20.↵
    1. Davies P,
    2. Koppel J

    . Mechanism-based treatments for Alzheimer’s disease. Dialogues Clin Neurosci 2009;11:159–69 doi:10.31887/DCNS.2009.11.2/pdavies pmid:19585951

    CrossRefPubMed
21. 21.↵
    1. Gilman S,
    2. Koller M,
    3. Black RS, et al

    ; for the AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553–62 doi:10.1212/01.WNL.0000159740.16984.3C pmid:15883316

    CrossRefPubMed
22. 22.↵
    1. Salloway S,
    2. Sperling R,
    3. Gilman S, et al; Bapineuzumab 201 Clinical Trial Investigators

    . A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061–70 doi:10.1212/WNL.0b013e3181c67808 pmid:19923550

    Abstract/FREE Full Text
23. 23.↵
    1. Black RS,
    2. Sperling RA,
    3. Safirstein B, et al

    . A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198–203 doi:10.1097/WAD.0b013e3181c53b00 pmid:20505438

    CrossRefPubMed
24. 24.↵
    1. Sperling RA,
    2. Jack CR,
    3. Black SE, et al

    . Amyloid Related Imaging Abnormalities (ARIA) in amyloid modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367–85 doi:10.1016/j.jalz.2011.05.2351 pmid:21784348

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Cummings J,
    2. Lee G,
    3. Zhong K, et al

    . Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (N Y) 2021;7:7:e12179 doi:10.1002/trc2.12179 pmid:34095440

    CrossRefPubMed
26. 26.
    1. van Dyck CH

    . Anti-Amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol Psychiatry 2018;83:311–19 doi:10.1016/j.biopsych.2017.08.010 pmid:28967385

    CrossRefPubMed
27. 27.↵
    1. Salloway S,
    2. Chalkias S,
    3. Barkhof F, et al

    . Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 2022;79:13–21 doi:10.1001/jamaneurol.2021.4161 pmid:34807243

    CrossRefPubMed
28. 28.↵
    1. Salloway S,
    2. Sperling R,
    3. Fox NC, et al

    ; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two Phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:322–33 doi:10.1056/NEJMoa1304839 pmid:24450891

    CrossRefPubMedWeb of Science
29. 29.
    1. Guthrie H,
    2. Honig LS,
    3. Lin H, et al

    . Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer’s disease treated with escalating doses for up to 133 weeks. J Alzheimers Dis 2020;76:967–79 doi:10.3233/JAD-200134 pmid:32568196

    CrossRefPubMed
30. 30.
    1. Landen JW,
    2. Cohen S,
    3. Billing CB, et al

    . Multiple-dose ponezumab for mild-to-moderate Alzheimer’s disease: safety and efficacy. Alzheimers Dement (N Y) 2017;3:339–47 doi:10.1016/j.trci.2017.04.003 pmid:29067341

    CrossRefPubMed
31. 31.↵
    1. Ostrowitzki S,
    2. Lasser RA,
    3. Dorflinger E

    , et al; SCarlet RoAD Investigators. A Phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther 2017;9:95 doi:10.1186/s13195-017-0318-y pmid:29221491

    CrossRefPubMed
32. 32.↵
    1. Doody RS,
    2. Thomas RG,
    3. Farlow M, et al

    ; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:311–21 doi:10.1056/NEJMoa1312889 pmid:24450890

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Kim SH,
    2. Ahn JH,
    3. Yang H, et al

    . Cerebral amyloid angiopathy aggravates perivascular clearance impairment in an Alzheimer’s disease mouse model. Acta Neuropathol Commun 2020;8:181 doi:10.1186/s40478-020-01042-0 pmid:33153499

    CrossRefPubMed
34. 34.↵
    1. Zago W,
    2. Schroeter S,
    3. Guido T, et al

    . Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimers Dement 2013;9:S105–15 doi:10.1016/j.jalz.2012.11.010 pmid:23583235

    CrossRefPubMed
35. 35.↵
    1. Antolini L,
    2. DiFrancesco JC,
    3. Zedde M, et al

    . Spontaneous ARIA-like events in cerebral amyloid angiopathy–related inflammation: a multicenter prospective longitudinal cohort study. Neurology 2021;97:e1809–22 doi:10.1212/WNL.0000000000012778 pmid:34531298

    Abstract/FREE Full Text
36. 36.↵
    1. Eng JA,
    2. Frosch MP,
    3. Choi K, et al

    . Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004;55:250–56 doi:10.1002/ana.10810 pmid:14755729

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Bohrmann B,
    2. Baumann K,
    3. Benz J, et al

    . Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis 2012;28:49–69 doi:10.3233/JAD-2011-110977 pmid:21955818

    CrossRefPubMed
38. 38.↵
    1. Sevigny J,
    2. Chiao P,
    3. Bussière T, et al

    . The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537:50–56 doi:10.1038/nature19323 pmid:27582220

    CrossRefPubMed
39. 39.↵
    1. Brashear HR,
    2. Ketter N,
    3. Bogert J, et al

    . Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab Phase III studies. J Alzheimers Dis 2018;66:1409–24 doi:10.3233/JAD-180675 pmid:30412493

    CrossRefPubMed
40. 40.↵
    1. Barakos J,
    2. Purcell D,
    3. Suhy J, et al

    . Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis 2022;9:211–20 doi:10.14283/jpad.2022.21 pmid:35542992

    CrossRefPubMed
41. 41.↵
    1. Yamada M

    . Cerebral amyloid angiopathy and gene polymorphisms. J Neurol Sci 2004;226:41–44 doi:10.1016/j.jns.2004.09.009 pmid:15537517

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Barakos J,
    2. Sperling R,
    3. Salloway S, et al

    . MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 2013;34:1958–65 doi:10.3174/ajnr.A3500 pmid:23578674

    Abstract/FREE Full Text
43. 43.↵
    1. Carlson C,
    2. Siemers E,
    3. Hake A, et al

    . Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer’s disease. Alzheimers Dement (Amst) 2016;2:75–85 doi:10.1016/j.dadm.2016.02.004 pmid:27239538

    CrossRefPubMed
44. 44.↵
    1. Sperling R,
    2. Salloway S,
    3. Brooks DJ, et al

    . Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012;11:241–49 doi:10.1016/S1474-4422(12)70015-7 pmid:22305802

    CrossRefPubMed
45. 45.↵
    1. Neema M,
    2. Guss ZD,
    3. Stankiewicz JM, et al

    . Normal findings on brain fluid-attenuated inversion recovery MR images at 3T. AJNR Am J Neuroradiol 2009;30:911–16 doi:10.3174/ajnr.A1514 pmid:19369605

    Abstract/FREE Full Text
46. 46.↵
    1. Kakeda S,
    2. Korogi Y,
    3. Hiai Y, et al

    . Pitfalls of 3D FLAIR brain imaging: a prospective comparison with 2D FLAIR. Acad Radiol 2012;19:1225–32 doi:10.1016/j.acra.2012.04.017 pmid:22818791

    CrossRefPubMed
47. 47.↵
    1. Kallmes DF,
    2. Hui FK,
    3. Mugler JP

    . Suppression of cerebrospinal fluid and blood flow artifacts in FLAIR MR imaging with a single-slab three-dimensional pulse sequence: initial experience. Radiology 2001;221:251–55 doi:10.1148/radiol.2211001712 pmid:11568348

    CrossRefPubMed
48. 48.↵
    1. Bartynski WS

    . Posterior reversible encephalopathy syndrome, Part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008;29:1036–42 doi:10.3174/ajnr.A0928 pmid:18356474

    CrossRefPubMed
49. 49.↵
    1. Stuckey SL,
    2. Goh TD,
    3. Heffernan T, et al

    . Hyperintensity in the subarachnoid space on FLAIR MRI. AJR Am J Roentgenol 2007;189:913–21 doi:10.2214/AJR.07.2424 pmid:17885065

    CrossRefPubMed
50. 50.↵
    1. Moraal B,
    2. Wattjes MP,
    3. Geurts JJG, et al

    . Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology 2010;255:154–63 doi:10.1148/radiol.09090814 pmid:20308453

    CrossRefPubMedWeb of Science
51. 51.↵
    1. VandeVrede L,
    2. Gibbs DM,
    3. Koestler M, et al

    . Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement (Amst) 2020;12:e12101 doi:10.1002/dad2.12101 pmid:33072846

    CrossRefPubMed
52. 52.↵
    1. Haller S,
    2. Haacke EM,
    3. Thurnher MM, et al

    . Susceptibility-weighted imaging: technical essentials and clinical neurologic applications. Radiology 2021;299:3–26 doi:10.1148/radiol.2021203071 pmid:33620291

    CrossRefPubMed
53. 53.↵
    1. Nandigam RK,
    2. Viswanathan A,
    3. Delgado P, et al

    . MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol 2009;30:338–43 doi:10.3174/ajnr.A1355 pmid:19001544

    Abstract/FREE Full Text
54. 54.↵
    1. Haller S,
    2. Vernooij MW,
    3. Kuijer JP, et al

    . Cerebral microbleeds: imaging and clinical significance. Radiology 2018;287:11–28 doi:10.1148/radiol.2018170803 pmid:29558307

    CrossRefPubMed
55. 55.↵
    1. Viswanathan A,
    2. Chabriat H

    . Cerebral microhemorrhage. Stroke 2006;37:550–55 doi:10.1161/01.STR.0000199847.96188.12 pmid:16397165

    Abstract/FREE Full Text
56. 56.↵
    1. Koenig LN,
    2. McCue LM,
    3. Grant E, et al

    . Lack of association between acute stroke, post-stroke dementia, race, and β-amyloid status. Neuroimage Clin 2021;29:102553 doi:10.1016/j.nicl.2020.102553 pmid:33524806

    CrossRefPubMed
57. 57.↵
    1. Cordonnier C,
    2. van der Flier WM,
    3. Sluimer JD, et al

    . Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006;66:1356–60 doi:10.1212/01.wnl.0000210535.20297.ae pmid:16682667

    Abstract/FREE Full Text
58. 58.↵
    1. Siemers ER,
    2. Sundell KL,
    3. Carlson C, et al

    . Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement 2016;12:110–20 doi:10.1016/j.jalz.2015.06.1893 pmid:26238576

    CrossRefPubMed
59. 59.↵
    1. Zonneveld HI,
    2. Goos JD,
    3. Wattjes MP, et al

    . Prevalence of cortical superficial siderosis in a memory clinic population. Neurology 2014;82:698–704 doi:10.1212/WNL.0000000000000150 pmid:24477113

    Abstract/FREE Full Text
60. 60.↵
    1. Shoamanesh A,
    2. Akoudad S,
    3. Himali JJ, et al

    . Cortical superficial siderosis in the general population: the Framingham Heart and Rotterdam studies. Int J Stroke 2021;16:798–808 doi:10.1177/1747493020984559 pmid:33478376

    CrossRefPubMed
61. 61.↵
    1. Barkhof F,
    2. Daams M,
    3. Scheltens P, et al

    . An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR Am J Neuroradiol 2013;34:1550–55 doi:10.3174/ajnr.A3475 pmid:23436056

    Abstract/FREE Full Text
62. 62.↵
    1. Cummings J,
    2. Aisen P,
    3. Apostolova LG, et al

    . Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis 2021;8:398–410 doi:10.14283/jpad.2021.41 pmid:34585212

    CrossRefPubMed
63. 63.↵
    1. Cummings J,
    2. Rabinovici GD,
    3. Atri A, et al

    . Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis 2022;9:221–30 doi:10.14283/jpad.2022.34 pmid:35542993

    CrossRefPubMed
64. 64.↵
    1. Aisen PS,
    2. Cummings J,
    3. Doody R, et al

    . The future of anti-amyloid trials. J Prev Alzheimers Dis 2020;7:146–51 doi:10.14283/jpad.2020.24 pmid:32463066

    CrossRefPubMed
65. 65.↵
    1. Wattjes MP,
    2. Lutterbey GG,
    3. Harzheim M, et al

    . Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol 2006;16:2067–73 doi:10.1007/s00330-006-0195-4 pmid:16649033

    CrossRefPubMedWeb of Science